Testosterone therapy induces molecular programming augmenting physiological adaptations to resistance exercise in older men.
Absorptiometry, Photon
Adaptation, Physiological
/ drug effects
Aged
Double-Blind Method
Drug Administration Schedule
Gene Expression Regulation
/ drug effects
Healthy Volunteers
Humans
Injections
Male
Metabolic Networks and Pathways
/ drug effects
Quadriceps Muscle
/ diagnostic imaging
Resistance Training
/ methods
Testosterone
/ administration & dosage
Treatment Outcome
Up-Regulation
Ageing
Protein turnover
Resistance exercise
Skeletal muscle
Testosterone
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
22
01
2019
revised:
14
05
2019
accepted:
12
06
2019
pubmed:
1
10
2019
medline:
28
7
2020
entrez:
1
10
2019
Statut:
ppublish
Résumé
The andropause is associated with declines in serum testosterone (T), loss of muscle mass (sarcopenia), and frailty. Two major interventions purported to offset sarcopenia are anabolic steroid therapies and resistance exercise training (RET). Nonetheless, the efficacy and physiological and molecular impacts of T therapy adjuvant to short-term RET remain poorly defined. Eighteen non-hypogonadal healthy older men, 65-75 years, were assigned in a random double-blinded fashion to receive, biweekly, either placebo (P, saline, n = 9) or T (Sustanon 250 mg, n = 9) injections over 6 week whole-body RET (three sets of 8-10 repetitions at 80% one-repetition maximum). Subjects underwent dual-energy X-ray absorptiometry, ultrasound of vastus lateralis (VL) muscle architecture, and knee extensor isometric muscle force tests; VL muscle biopsies were taken to quantify myogenic/anabolic gene expression, anabolic signalling, muscle protein synthesis (D Testosterone adjuvant to RET augmented total fat-free mass (P=0.007), legs fat-free mass (P=0.02), and appendicular fat-free mass (P=0.001) gains while decreasing total fat mass (P=0.02). Augmentations in VL muscle thickness, fascicle length, and quadriceps cross-section area with RET occured to a greater extent in T (P < 0.05). Sum strength (P=0.0009) and maximal voluntary contract (e.g. knee extension at 70°) (P=0.002) increased significantly more in the T group. Mechanistically, both muscle protein synthesis rates (T: 2.13 ± 0.21%·day Administration of T adjuvant to RET enhanced skeletal muscle mass and performance, while up-regulating myogenic gene programming, myocellular translational efficiency and capacity, collectively resulting in higher protein turnover, and net protein accretion. T coupled with RET is an effective short-term intervention to improve muscle mass/function in older non-hypogonadal men.
Sections du résumé
BACKGROUND
The andropause is associated with declines in serum testosterone (T), loss of muscle mass (sarcopenia), and frailty. Two major interventions purported to offset sarcopenia are anabolic steroid therapies and resistance exercise training (RET). Nonetheless, the efficacy and physiological and molecular impacts of T therapy adjuvant to short-term RET remain poorly defined.
METHODS
Eighteen non-hypogonadal healthy older men, 65-75 years, were assigned in a random double-blinded fashion to receive, biweekly, either placebo (P, saline, n = 9) or T (Sustanon 250 mg, n = 9) injections over 6 week whole-body RET (three sets of 8-10 repetitions at 80% one-repetition maximum). Subjects underwent dual-energy X-ray absorptiometry, ultrasound of vastus lateralis (VL) muscle architecture, and knee extensor isometric muscle force tests; VL muscle biopsies were taken to quantify myogenic/anabolic gene expression, anabolic signalling, muscle protein synthesis (D
RESULTS
Testosterone adjuvant to RET augmented total fat-free mass (P=0.007), legs fat-free mass (P=0.02), and appendicular fat-free mass (P=0.001) gains while decreasing total fat mass (P=0.02). Augmentations in VL muscle thickness, fascicle length, and quadriceps cross-section area with RET occured to a greater extent in T (P < 0.05). Sum strength (P=0.0009) and maximal voluntary contract (e.g. knee extension at 70°) (P=0.002) increased significantly more in the T group. Mechanistically, both muscle protein synthesis rates (T: 2.13 ± 0.21%·day
CONCLUSIONS
Administration of T adjuvant to RET enhanced skeletal muscle mass and performance, while up-regulating myogenic gene programming, myocellular translational efficiency and capacity, collectively resulting in higher protein turnover, and net protein accretion. T coupled with RET is an effective short-term intervention to improve muscle mass/function in older non-hypogonadal men.
Identifiants
pubmed: 31568675
doi: 10.1002/jcsm.12472
pmc: PMC6903447
doi:
Substances chimiques
Testosterone
3XMK78S47O
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1276-1294Subventions
Organisme : Medical Research Council
ID : MR/P021220/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R502364/1
Pays : United Kingdom
Informations de copyright
© 2019 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
Med Sci Sports Exerc. 2008 Feb;40(2):223-33
pubmed: 18202581
J Clin Endocrinol Metab. 2006 Aug;91(8):3024-33
pubmed: 16705073
J Cachexia Sarcopenia Muscle. 2014 Mar;5(1):19-25
pubmed: 24009031
Mediators Inflamm. 2013;2013:539156
pubmed: 24089589
J Sex Med. 2016 Jul;13(7):1029-46
pubmed: 27209182
Acta Physiol Scand. 1993 Jun;148(2):199-207
pubmed: 8352031
J Gerontol A Biol Sci Med Sci. 2000 Feb;55(2):B95-105
pubmed: 10737684
J Appl Physiol (1985). 2004 Apr;96(4):1530-40
pubmed: 14565966
Physiol Rep. 2015 Nov;3(11):
pubmed: 26564061
J Clin Endocrinol Metab. 2003 Apr;88(4):1478-85
pubmed: 12679426
J Gerontol A Biol Sci Med Sci. 2018 Mar 14;73(4):539-545
pubmed: 28977366
Eur J Endocrinol. 2014 Jul;171(1):77-88
pubmed: 24760536
JCI Insight. 2017 Sep 7;2(17):
pubmed: 28878131
Eur J Sport Sci. 2016 Sep;16(6):633-44
pubmed: 26289597
Front Physiol. 2012 Jul 11;3:260
pubmed: 22934016
J Neurol Neurosurg Psychiatry. 1987 Nov;50(11):1461-7
pubmed: 3694206
Indian J Urol. 2014 Jan;30(1):2-7
pubmed: 24497673
Sports Med. 2010 Dec 1;40(12):1037-53
pubmed: 21058750
Clin J Am Soc Nephrol. 2010 Jun;5(6):996-1002
pubmed: 20498251
J Physiol. 2008 Aug 1;586(15):3701-17
pubmed: 18556367
Scand J Med Sci Sports. 2017 Jan;27(1):4-25
pubmed: 27263489
J Appl Physiol (1985). 2004 Jul;97(1):243-8
pubmed: 15033970
Am J Physiol. 1995 Nov;269(5 Pt 1):E820-6
pubmed: 7491931
FASEB J. 2015 Nov;29(11):4485-96
pubmed: 26169934
Exp Gerontol. 2015 Sep;69:148-58
pubmed: 26079649
Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1325-32
pubmed: 16868226
Am J Physiol Endocrinol Metab. 2014 Mar 1;306(5):E571-9
pubmed: 24381002
J Appl Physiol (1985). 2014 Mar 15;116(6):693-702
pubmed: 24458751
J Cachexia Sarcopenia Muscle. 2017 Dec;8(6):1081-1083
pubmed: 29098794
J Strength Cond Res. 2009 Nov;23(8):2179-87
pubmed: 19826309
J Physiol. 2003 Feb 15;547(Pt 1):247-54
pubmed: 12562960
J Clin Endocrinol Metab. 2004 Oct;89(10):4789-96
pubmed: 15472164
J Clin Endocrinol Metab. 2017 Apr 1;102(4):1161-1173
pubmed: 28324103
Am J Respir Crit Care Med. 2004 Oct 15;170(8):870-8
pubmed: 15271690
N Engl J Med. 1996 Jul 4;335(1):1-7
pubmed: 8637535
Endocrinology. 2010 Feb;151(2):628-38
pubmed: 20022929
J Clin Endocrinol Metab. 1997 Jun;82(6):1661-7
pubmed: 9177359
Br J Pharmacol. 2008 Jun;154(3):522-8
pubmed: 18414389
Mol Endocrinol. 2009 Nov;23(11):1927-33
pubmed: 19762544
J Appl Physiol (1985). 2008 Dec;105(6):1754-60
pubmed: 18832756
J Clin Endocrinol Metab. 1996 Oct;81(10):3469-75
pubmed: 8855787
Eur J Appl Physiol. 2010 Jul;109(4):631-9
pubmed: 20191287
Horm Mol Biol Clin Investig. 2011 Oct 1;8(1):431-44
pubmed: 25961343
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
J Strength Cond Res. 2013 Feb;27(2):556-61
pubmed: 23090317
Acta Physiol Scand. 1994 Feb;150(2):211-9
pubmed: 8191900
Diabetes Care. 2005 Jul;28(7):1636-42
pubmed: 15983313
Med Sci Sports Exerc. 2004 Sep;36(9):1499-506
pubmed: 15354030
Med Sci Sports Exerc. 1989 Jun;21(3):283-7
pubmed: 2733577
Horm Metab Res. 1993 May;25(5):268-70
pubmed: 8330862
Am J Med. 2019 Sep;132(9):1069-1077.e4
pubmed: 30953635
Endocrinology. 1962 Aug;71:314-20
pubmed: 14497529
Int J Impot Res. 2008 Jul-Aug;20(4):378-87
pubmed: 18480825
Methods Enzymol. 1996;264:484-509
pubmed: 8965721
Diabetes. 2005 Apr;54(4):1000-8
pubmed: 15793238
J Anim Sci. 2013 Jul;91(7):3155-67
pubmed: 23798514
J Physiol. 2003 Mar 15;547(Pt 3):977-87
pubmed: 12562918
Eur J Endocrinol. 2013 Jan 17;168(2):243-51
pubmed: 23169695
Physiol Res. 2017 Mar 31;66(1):1-14
pubmed: 27982690
J Physiol. 2007 Jan 15;578(Pt 2):579-93
pubmed: 17095559
Drug Saf. 2016 Feb;39(2):117-30
pubmed: 26482385
Front Physiol. 2018 Jul 04;9:834
pubmed: 30022953
Int J Biochem Cell Biol. 2010 Jun;42(6):813-27
pubmed: 19931639
J Am Geriatr Soc. 2010 Jun;58(6):1134-43
pubmed: 20722847
N Engl J Med. 2004 Jan 29;350(5):482-92
pubmed: 14749457
J Physiol. 2017 Mar 1;595(5):1447-1448
pubmed: 28105708
Am J Physiol Endocrinol Metab. 2002 Mar;282(3):E601-7
pubmed: 11832363
In Vivo. 2009 Jul-Aug;23(4):567-75
pubmed: 19567392
Pflugers Arch. 1992 Jun;421(2-3):274-9
pubmed: 1326749
Int J Androl. 1999 Aug;22(4):261-5
pubmed: 10442299
Acta Neuropathol. 1998 Apr;95(4):352-60
pubmed: 9560012
Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1172-81
pubmed: 11701431
Clin Interv Aging. 2008;3(1):25-44
pubmed: 18488876
Am J Physiol Endocrinol Metab. 2015 Jun 15;308(12):E1035-42
pubmed: 25898953
Front Physiol. 2017 Sep 15;8:713
pubmed: 28966596
Endocrinology. 2006 Jun;147(6):3093-106
pubmed: 16527841
PLoS One. 2012;7(12):e51180
pubmed: 23240002
PeerJ. 2018 Jul 27;6:e5338
pubmed: 30065891
Nature. 2007 Nov 29;450(7170):736-40
pubmed: 18046414
Clin Interv Aging. 2007;2(4):577-90
pubmed: 18225458
Endocrinology. 2003 Nov;144(11):5081-8
pubmed: 12960001
Br J Nutr. 1990 Nov;64(3):691-704
pubmed: 1702317
JAMA. 2013 Nov 6;310(17):1829-36
pubmed: 24193080
Sports Med. 2004;34(12):809-24
pubmed: 15462613
Lancet. 2015 May 9;385(9980):1806-8
pubmed: 25684588
Rapid Commun Mass Spectrom. 2013 Aug 15;27(15):1769-77
pubmed: 23821570
PLoS One. 2007 May 23;2(5):e465
pubmed: 17520024
Front Psychol. 2013 Nov 26;4:863
pubmed: 24324449
Aging Clin Exp Res. 2002 Feb;14(1):35-41
pubmed: 12027150
FEBS Lett. 2014 May 21;588(10):1935-41
pubmed: 24726723
Eur J Appl Physiol. 2011 Sep;111(9):2249-59
pubmed: 21327794
J Gerontol A Biol Sci Med Sci. 2003 Dec;58(12):M1103-10
pubmed: 14684707
Med Sci Sports Exerc. 2005 Oct;37(10):1664-72
pubmed: 16260965
J Cachexia Sarcopenia Muscle. 2019 Dec;10(6):1276-1294
pubmed: 31568675
Sports Med. 2018 Mar;48(Suppl 1):53-64
pubmed: 29368185
FASEB J. 2014 Apr;28(4):1891-7
pubmed: 24443372
Baillieres Clin Endocrinol Metab. 1998 Oct;12(3):521-34
pubmed: 10332571
Med Sci Sports Exerc. 2015 Sep;47(9):1922-31
pubmed: 25539479
J Am Geriatr Soc. 2003 Jan;51(1):101-15; discussion 115
pubmed: 12534854
J Musculoskelet Neuronal Interact. 2011 Dec;11(4):286-97
pubmed: 22130137
Adv Prev Med. 2011;2011:984683
pubmed: 21991450
J Clin Endocrinol Metab. 2010 Jun;95(6):2560-75
pubmed: 20525906
Am J Physiol Endocrinol Metab. 2002 Jul;283(1):E154-64
pubmed: 12067856
Med Sci Sports Exerc. 1999 Nov;31(11):1528-34
pubmed: 10589853
Am J Physiol. 1998 Nov;275(5):E864-71
pubmed: 9815007
Mol Cell Endocrinol. 2013 Jan 30;365(2):174-86
pubmed: 23116773
J Gerontol A Biol Sci Med Sci. 2010 Nov;65(11):1215-9
pubmed: 20601412
J Physiol. 2016 Dec 15;594(24):7399-7417
pubmed: 27654940
Sci Rep. 2017 Aug 17;7(1):8593
pubmed: 28819168
Biochem J. 1980 Oct 15;192(1):349-53
pubmed: 6272701